With 9.56 million shares changed hands, the volume of the stock remained heavier than its average volume of 7.13 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $8.77 whereas the lowest price it dropped to was $8.08. The 52-week range on IBRX shows that it touched its highest point at $10.53 and its lowest point at $1.25 during that stretch. It currently has a 1-year price target of $7.50. Beta for the stock currently stands at 0.96.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of IBRX was up-trending over the past week, with a rise of 3.38%, but this was up by 33.87% over a month. Three-month performance surged to 95.73% while six-month performance rose 120.27%. The stock gained 49.10% in the past year, while it has gained 64.54% so far this year. A look at the trailing 12-month EPS for IBRX yields -1.13 with Next year EPS estimates of -0.52. For the next quarter, that number is -0.20. This implies an EPS growth rate of 35.22% for this year and 30.20% for next year. EPS is expected to decline by -1.70% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 1.17%.
Float and Shares Shorts:
At present, 670.87 million IBRX shares are outstanding with a float of 137.56 million shares on hand for trading. On 2024-04-15, short shares totaled 54.84 million, which was 810.0 higher than short shares on 1710460800. In addition to Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc. as the firm’s Executive Chairman of the Board and Global Chief Scientific & Medical Officer, Mr. Richard Gerald Adcock serves as its President, CEO & Director.
Institutional Ownership:
Through their ownership of 0.087139994 of IBRX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2023-12-31, IBRX reported revenue of $139000.0 and operating income of -$84503000.0. The EBITDA in the recently reported quarter was -$115741000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for IBRX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
